To begin to characterize the role of ADAR1-mediated editing in DLBCL, we concentrated on A-to-I RNA editing sites that can be assigned to a gene locus and that were enriched in DLBCL patient samples. The gene discussed is ADAR; the disease is diffuse large B-cell lymphoma.